Mesalamine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Crohn's Disease

• Azathioprine
• Budesonide
• Methotrexate
• Prednisone

Also listed for Ulcerative Colitis

• Sulfasalazine

Other medications in Gastrointestinal

• Omeprazole
• Pantoprazole
• Ranitidine
• Sucralfate
• Dapsone
• Dicyclomine
• Esomeprazole
• Famotidine

What Mesalamine is approved for (FDA label)

APRISO ® is indicated for the maintenance of remission of ulcerative colitis in adults. APRISO is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Mesalamine (FDA label)

Extended-release capsules: 0.375 g mesalamine in a light blue opaque gelatin capsule with the letters “G” and “M” imprinted on either side of a black band. Extended-release capsules: 0.375 g ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7951139c-b271-45a4-b523-34b23800917b. SPL document ID: 5a0ee848-80a0-294e-e063-6394a90a08aa. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Mesalamine (FDA label)

The following clinically significant adverse reactions are described elsewhere in labeling: Renal Impairment [see Warnings and Precautions ( 5.1 )] Mesalamine-Induced Acute Intolerance Syndrome [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] Hepatic Failure [see Warnings and Precautions ( 5.4 )] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5) ] Photosensitivity [see Warnings and Precautions ( 5.6 )] Nephrolithiasis [see Warnings and Precautions ( 5.7 )] Risks in Patients with Phenylketonuria [see Warnings and Precautions ( 5.8 )] Most common adverse reactions (≥3%) are: headache, diarrhea, upper abdominal pain, nausea, and nasopharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7951139c-b271-45a4-b523-34b23800917b. SPL document ID: 5a0ee848-80a0-294e-e063-6394a90a08aa. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Mesalamine (FDA label)

APRISO is contraindicated in patients with hypersensitivity to salicylates or aminosalicylates or to any of the components of APRISO capsules [see Warnings and Precautions ( 5.3 ), Adverse Reactions ( 6.2 ), Description ( 11 )] . Known or suspected hypersensitivity to salicylates, aminosalicylates, or any component of APRISO capsules. ( 4 , 5.3 )

Source: FDA prescribing information (DailyMed). Set ID: 7951139c-b271-45a4-b523-34b23800917b. SPL document ID: 5a0ee848-80a0-294e-e063-6394a90a08aa. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Mesalamine (FDA label)

Renal Impairment: Assess renal function at the beginning of treatment and periodically during treatment. Evaluate the risks and benefits in patients with known renal impairment or taking nephrotoxic drugs; monitor renal function.

Source: FDA prescribing information (DailyMed). Set ID: 7951139c-b271-45a4-b523-34b23800917b. SPL document ID: 5a0ee848-80a0-294e-e063-6394a90a08aa. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Mesalamine (FDA label)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. ( 7.2 ) Azathioprine or 6-Mercaptopurine: Increased risk of blood disorders; monitor complete blood cell counts and platelet counts. ( 7.3 ) 7.1 Antacids Because the dissolution of the coating of the granules in APRISO capsules depends on pH, avoid co-administration of APRISO capsules with antacids [see Dosage and Administration (2) ] . 7.2 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of nephrotoxicity.

Source: FDA prescribing information (DailyMed). Set ID: 7951139c-b271-45a4-b523-34b23800917b. SPL document ID: 5a0ee848-80a0-294e-e063-6394a90a08aa. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.